Riverhead Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Riverhead Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$144K	Buy	2,400 +100	+4%	+$7.43K	0.01%	1240
2019 Q2	$194K	Hold	2,300	–	–	0.01%	1161
2019 Q1	$220K	Hold	2,300	–	–	0.01%	1075
2018 Q4	$163K	Buy	2,300 +100	+5%	+$7.67K	0.01%	1156
2018 Q3	$188K	Buy	2,200 +600	+38%	+$60.1K	0.01%	1222
2018 Q2	$185K	Hold	1,600	–	–	0.01%	1128
2018 Q1	$129K	Buy	+1,600	New	+$123K	0.01%	1255
2017 Q1	–	Sell	-500	Closed	-$17K	–	1525
2016 Q4	$17K	Hold	500	–	–	﹤0.01%	1435
2016 Q3	$13K	Sell	500 -5,792	-92%	-$135K	﹤0.01%	1416
2016 Q2	$324K	Buy	6,292 +5,900	+1,505%	+$154K	0.01%	712
2016 Q1	$12K	Buy	+392	New	+$10.9K	﹤0.01%	1416

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Riverhead Capital Management's ENTA Position: Q3 2019 in Review

Riverhead Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 4.3% in Q3 2019, buying an estimated $7.43K and bringing the position to 2,400 shares worth $144K. The position accounts for 0.01% of the portfolio, ranked #1240.

Riverhead Capital Management first reported a position in ENTA in Q1 2016 and has held it in 11 quarters since. The position peaked at $324K in Q2 2016. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Riverhead Capital Management held 2,400 shares of Enanta Pharmaceuticals worth $144K as of Q3 2019.
Riverhead Capital Management bought 100 Enanta Pharmaceuticals shares in Q3 2019, an estimated $7.43K.
Enanta Pharmaceuticals made up 0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1240 holding.
Riverhead Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2016 and has held it in 11 quarters since.
Riverhead Capital Management's Enanta Pharmaceuticals position peaked at $324K in Q2 2016.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.